Intervention

INCAGN02385

ClinicalTrials.gov intervention label

Clinical trials1

Recruiting0

Common conditions17

Lead sponsors shown1

Clinical trials

1 shown

A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesNCT03538028 · 2018-06-18

COMPLETED

Common conditions

Cervical Cancer1 Diffuse Large B-cell Lymphoma1 Esophageal Cancer1 Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])1 Hepatocellular Carcinoma1 Melanoma (Uveal Melanoma Excluded)1 Merkel Cell Carcinoma1 Mesothelioma1 Microsatellite Instability (MSI)-High Endometrial Cancer1 MSI-high Colorectal Cancer1 Non-small Cell Lung Cancer (NSCLC)1 Ovarian Cancer1 Renal Cell Carcinoma (RCC)1 Small Cell Lung Cancer (SCLC)1 Squamous Cell Carcinoma of the Head and Neck (SCCHN)1 Triple-negative Breast Cancer1 Urothelial Carcinoma1

Leading sponsors

Incyte Biosciences International Sàrl1

Trial status mix

COMPLETED1

Phase mix

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.